Lantern Pharma
LTRN
39 hedge funds and large institutions have $12M invested in Lantern Pharma in 2026 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 6 closing their positions.
319% more capital invested
Capital invested by funds: $2.87M → $12M (+$9.15M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
33% more call options, than puts
Call options by funds: $4K | Put options by funds: $3K
18% more funds holding
Funds holding: 33 → 39 (+6)
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
3.85% more ownership
Funds ownership: 18.75% → 22.59% (+3.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Empery Asset Management
New York
|
+$2.47M |
| 2 |
CM
CM Management
Gulf Breeze,
Florida
|
+$733K |
| 3 |
Renaissance Technologies
New York
|
+$513K |
| 4 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$273K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$140K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BIOS Capital Management
Fort Worth,
Texas
|
-$1.8M |
| 2 |
VC
Voss Capital
Houston,
Texas
|
-$68.5K |
| 3 |
BlackRock
New York
|
-$67.2K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$62.5K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$25.9K |
LTRN Hedge Fund Activity: Q2 2026 in Review
39 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q2 2026, worth a combined $12M — up 319% from $2.87M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new LTRN positions and 6 closed out — a net gain of 6 holders — while 9 added to existing stakes and 8 trimmed.
The largest buyer was Empery Asset Management, opening a new position worth an estimated $2.47M. The largest seller was BIOS Capital Management, cutting an estimated $1.8M.
- 39 institutional investors held Lantern Pharma (LTRN) as of Q2 2026, up from 33 in Q1 2026.
- Funds reported $12M of Lantern Pharma stock for Q2 2026, up 319% quarter-over-quarter.
- 12 funds opened new Lantern Pharma positions in Q2 2026 and 6 closed out, a net change of +6 holders.
- The largest Lantern Pharma buyer in Q2 2026 was Empery Asset Management, an estimated $2.47M added.
- The largest Lantern Pharma seller in Q2 2026 was BIOS Capital Management, an estimated $1.8M sold.
Based on aggregated 13F filings for Q2 2026.